It’s common for medications to be marketed under multiple brand names, especially when they serve different purposes. A recent example of this is tirzepatide, available as both Mounjaro and Zepbound. Initially, tirzepatide was researched for managing Type 2 diabetes. However, during clinical studies, it became clear that it could also promote significant weight loss, which led to its FDA approval for both diabetes management and weight reduction.
Many hormones in the gut play roles in managing blood sugar and regulating weight. One key hormone is GLP-1, which has led to the development of a specific group of diabetes treatments known as GLP-1 receptor agonists (GLP-1RAs). Another important hormone is GIP. Similar to GLP-1, GIP also promotes insulin release when we eat, though individuals with type 2 diabetes may show resistance to this effect. As a GLP-1 receptor agonist, Tirzepatide may effectively help with diabetes treatment and present a novelty approach in this field. [1]
What is Tirzepatide?
Tirzepatide is a peptide that acts as an agonist for both GLP-1 and GIP receptors, mimicking the effects of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones, released in response to sugar intake, are vital in regulating blood sugar. Mounjaro, which contains tirzepatide, is primarily FDA-approved for managing type 2 diabetes and controlling blood glucose levels. However, it has shown significant potential for promoting weight loss, and some healthcare providers prescribe it off-label for this purpose despite it not yet being FDA-approved specifically for weight reduction. [1]
Tirzepatide for Diabetes
Tirzepatide has demonstrated promising effects on glycemic control and weight reduction for individuals with type 2 diabetes. In a phase 2 clinical trial, it showed a considerable decrease in HbA1c levels, a key indicator of long-term blood glucose control, compared to both a placebo and other diabetes treatments. Additionally, patients treated with tirzepatide achieved weight loss of up to 13%, offering substantial benefits for those managing both obesity and diabetes. [2]
How Does Tirzepatide Work
Tirzepatide has shown promise in enhancing blood sugar management and supporting weight loss in individuals with type 2 diabetes. During a phase 2 clinical trial, tirzepatide led to a marked reduction in HbA1c levels (a key indicator of average blood sugar over time) when compared to both a placebo and other diabetes treatments. Additionally, patients experienced weight loss of up to 13%, which is particularly beneficial for those facing the dual challenges of obesity and diabetes. [2]
Once administered, tirzepatide slows down digestion, which can aid in controlling portion sizes and curbing hunger. By delaying stomach emptying and slowing nutrient absorption, it contributes to prolonged feelings of fullness which can be beneficial both for diabetes treatment and weight loss.
Additionally, tirzepatide influences certain areas of the brain (particularly the hypothalamus) that play a role in appetite regulation and food choices. Through its impact on these brain regions, tirzepatide helps manage cravings, supports appetite control, and encourages healthier eating habits which can all aid in treating diabetes.
Benefits of Tirzepatide
Tirzepatide has demonstrated significant effectiveness in lowering blood sugar levels for individuals with type 2 diabetes. In clinical studies, it outperformed other GLP-1 receptor agonists in achieving better blood sugar control. Additionally, Tirzepatide may aid in weight loss, which is necessary for those with type 2 diabetes who struggle with being overweight or obese. [1][2]
Tirzepatide vs Other Diabetes Medications
Tirzepatide stands out from other diabetes medications due to its unique dual-action mechanism. Unlike most treatments that target only one hormone, tirzepatide affects both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
Like any medication, tirzepatide may lead to certain side effects. The most frequently reported side effects in clinical trials are gastrointestinal issues, including nausea, vomiting, and diarrhea. Additionally, when used alongside insulin or insulin secretagogues, tirzepatide has been linked to a higher risk of hypoglycemia, or low blood sugar levels.
Studies on Tirzepatide and Diabetes
The SURPASS-1 study involved 478 adults with type 2 diabetes from India, Japan, Mexico, and the United States. These participants had diabetes that was not well-controlled (A1C between 7% and 9.5%) and were not taking any diabetes medications, with a BMI of at least 23. Participants were assigned to receive weekly injections of either tirzepatide at doses of 5mg, 10mg, or 15mg, or a placebo. The primary outcome measured was the change in A1C after 40 weeks of treatment.
At the study’s start, participants had an average A1C of 7.9%, were approximately 54 years old on average, and had a mean BMI of 32. Being early in their diabetes management journey, they had lived with diabetes for about 4.7 years on average.
After 40 weeks, all doses of tirzepatide significantly outperformed the placebo in reducing A1C, with decreases of -1.9%, -1.9%, and -2.1% for the 5mg, 10mg, and 15mg groups. Remarkably, 31% to 52% of participants in the tirzepatide groups achieved a A1C levels below 5.7%. Weight loss was also dose-dependent: the 5mg group lost an average of 7kg, the 10mg group 7.8kg, and the 15mg group 9.5kg, compared to only 0.7kg in the placebo group. Furthermore, over 25% of those on the highest tirzepatide dose saw a weight reduction of at least 15%. While A1C reductions plateaued around 20 weeks, weight loss continued through week 40, indicating tirzepatide’s potential for further weight loss benefits apart from helping with diabetes. [3]
Tirzepatide vs Semaglutide Study
In the SURPASS-2 trials scientists addressed the effectiveness of tirzepatide vs semaglutide. Participants with type 2 diabetes received weekly doses of tirzepatide similar to those used in the previous trial, along with a 1mg dose of semaglutide, another FDA-approved GLP-1 agonist for diabetes treatment, for 40 weeks.
Tirzepatide demonstrated a reduction in A1C levels ranging from 2.01% to 2.3%, depending on the dosage, while semaglutide achieved a reduction of 1.86%. The trial findings also highlighted a more significant weight loss among participants taking tirzepatide compared to those on semaglutide. [4]
Tirzepatide vs Insulin Degludec Study
The SURPASS-3 trial evaluated the effectiveness of tirzepatide against insulin degludec, another injectable medication for diabetes that has received FDA approval.
This study focused on individuals with type 2 diabetes who had not previously been treated with insulin and who were not achieving adequate control with metformin alone or in combination with SGLT2 inhibitors.
After 52 weeks of treatment, those receiving tirzepatide demonstrated significantly greater reductions in A1C levels compared to participants taking insulin degludec. [5]
What’s the Dosage?
The dosage for tirzepatide can vary based on the intended outcome. For managing type 2 diabetes, starting with a 2.5 mg dose is also advisable, with gradual increases every four weeks. However, this initial 2.5 mg dose is primarily for initiating treatment and is not specifically designed for blood sugar control. The day of the weekly injection can be adjusted as necessary, provided there is at least a 72-hour gap between doses.
For weight loss, it’s recommended to begin with a 2.5 mg injection once a week. If the medication is well tolerated after four weeks, the dose can be increased to 5 mg. Subsequent adjustments can be made every four weeks, increasing by increments of 2.5 mg as needed. It's important to note that the maximum dosage allowed is 15 mg per week.
How is Tirzepatide Used?
Always adhere to the instructions on your prescription label and consult your doctor or a healthcare professional for any clarifications. It is important that you take this medication exactly as directed.. Never take more or less than directed, or use it more frequently than recommended.
What are the Risks
As with any medication, Tirzepatide may lead to certain side effects. While the severity and frequency of these side effects can vary, most are temporary and typically resolve within a few days to weeks. However, if you experience persistent, bothersome, or severe symptoms, it's essential to reach out to your healthcare provider. Clinical trial participants have reported several common side effects associated with Tirzepatide. [6]
Nausea;
Diarrhea;
Decreased appetite;
Constipation;
Hypoglycemia;
Vomiting.
Final Thoughts
People experiencing early signs of diabetes may see normalized blood sugars and significant weight loss with tirzepatide. As a dual agonist for GLP-1 and GIP receptors, it mimics the actions of satiety hormones, offering a unique approach to simultaneously addressing obesity and glucose control. Evidence from clinical trials highlights its efficacy in facilitating significant weight loss, making it a valuable tool in combating diabetes and obesity-related health issues.
Keep in mind that tirzepatide is not a cure-all medication. It should be integrated into a holistic strategy that includes dietary modifications, regular physical activity, and lifestyle adjustments to achieve sustainable weight loss and effective glycemic control in combating diabetes.
Reviewed by
